TY - JOUR
T1 - European consensus for the diagnosis of MCI and mild dementia
T2 - Preparatory phase
AU - Festari, Cristina
AU - Massa, Federico
AU - Cotta Ramusino, Matteo
AU - Gandolfo, Federica
AU - Nicolosi, Valentina
AU - Orini, Stefania
AU - Aarsland, Dag
AU - Agosta, Federica
AU - Babiloni, Claudio
AU - Boada, Mercè
AU - Borroni, Barbara
AU - Cappa, Stefano
AU - Dubois, Bruno
AU - Frederiksen, Kristian S.
AU - Froelich, Lutz
AU - Garibotto, Valentina
AU - Georges, Jean
AU - Haliassos, Alexander
AU - Hansson, Oskar
AU - Jessen, Frank
AU - Kamondi, Anita
AU - Kessels, Roy P.C.
AU - Morbelli, Silvia
AU - O'Brien, John T.
AU - Otto, Markus
AU - Perret-Liaudet, Armand
AU - Pizzini, Francesca B.
AU - Ritchie, Craig W.
AU - Scheltens, Philip
AU - Vandenbulcke, Mathieu
AU - Vanninen, Ritva
AU - Verhey, Frans
AU - Vernooij, Meike W.
AU - Yousry, Tarek
AU - Van Der Flier, Wiesje M.
AU - Nobili, Flavio
AU - Frisoni, Giovanni B.
PY - 2023
Y1 - 2023
N2 - Introduction: Etiological diagnosis of neurocognitive disorders of middle-old age relies on biomarkers, although evidence for their rational use is incomplete. A European task force is defining a diagnostic workflow where expert experience fills evidence gaps for biomarker validity and prioritization. We report methodology and preliminary results. Methods: Using a Delphi consensus method supported by a systematic literature review, 22 delegates from 11 relevant scientific societies defined workflow assumptions. Results: We extracted diagnostic accuracy figures from literature on the use of biomarkers in the diagnosis of main forms of neurocognitive disorders. Supported by this evidence, panelists defined clinical setting (specialist outpatient service), application stage (MCI-mild dementia), and detailed pre-assessment screening (clinical-neuropsychological evaluations, brain imaging, and blood tests). Discussion: The Delphi consensus on these assumptions set the stage for the development of the first pan-European workflow for biomarkers’ use in the etiological diagnosis of middle-old age neurocognitive disorders at MCI-mild dementia stages. Highlights: Rational use of biomarkers in neurocognitive disorders lacks consensus in Europe. A consensus of experts will define a workflow for the rational use of biomarkers. The diagnostic workflow will be patient-centered and based on clinical presentation. The workflow will be updated as new evidence accrues.
AB - Introduction: Etiological diagnosis of neurocognitive disorders of middle-old age relies on biomarkers, although evidence for their rational use is incomplete. A European task force is defining a diagnostic workflow where expert experience fills evidence gaps for biomarker validity and prioritization. We report methodology and preliminary results. Methods: Using a Delphi consensus method supported by a systematic literature review, 22 delegates from 11 relevant scientific societies defined workflow assumptions. Results: We extracted diagnostic accuracy figures from literature on the use of biomarkers in the diagnosis of main forms of neurocognitive disorders. Supported by this evidence, panelists defined clinical setting (specialist outpatient service), application stage (MCI-mild dementia), and detailed pre-assessment screening (clinical-neuropsychological evaluations, brain imaging, and blood tests). Discussion: The Delphi consensus on these assumptions set the stage for the development of the first pan-European workflow for biomarkers’ use in the etiological diagnosis of middle-old age neurocognitive disorders at MCI-mild dementia stages. Highlights: Rational use of biomarkers in neurocognitive disorders lacks consensus in Europe. A consensus of experts will define a workflow for the rational use of biomarkers. The diagnostic workflow will be patient-centered and based on clinical presentation. The workflow will be updated as new evidence accrues.
KW - consensus
KW - Delphi procedure
KW - etiological diagnosis
KW - imaging
KW - major neurocognitive disorder
KW - MCI
KW - mild dementia – biomarker
KW - neurocognitive disorders
U2 - 10.1002/alz.12798
DO - 10.1002/alz.12798
M3 - Article
C2 - 36209379
AN - SCOPUS:85139755547
SN - 1552-5260
VL - 19
SP - 1729
EP - 1741
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 5
ER -